Curis And Autolus Rise On EHA Abstract Data
Potential Advances In AML and NHL
Promising early-stage data from two companies looking to break into crowded hemato-oncology markets.
You may also be interested in...
The US major won a positive opinion from the EU CHMP for Breyanzi with hopes the advantage of outpatient administration could help combat the lack of market impetus for CAR-T therapies.
Autolus, Scholar Rock, Rocket and Pfizer have managed to convince the European Medicines Agency that their investigational treatments merit a place on the regulator’s priory medicines scheme.
Beam is the latest allogeneic CAR-T developer to face a regulatory hold-up, but other candidates using its pioneering base-editing technology are now progressing.